A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Clinical Trial ID NCT01125800

Rank	Title	Journal	Year	PubWeight™‹?›
1	Unraveling the therapeutic potential of the Hedgehog pathway in cancer.	Nat Med	2013	2.55
2	Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.	Nat Rev Clin Oncol	2015	2.02
3	Treatment of high-grade glioma in children and adolescents.	Neuro Oncol	2011	1.27
4	Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting.	Sarcoma	2012	0.99
5	The rationale for targeted therapies in medulloblastoma.	Neuro Oncol	2013	0.92
6	Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer.	Cancer Growth Metastasis	2015	0.90
7	Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy.	Expert Rev Mol Med	2015	0.87
8	Targeted therapies for bone sarcomas.	Bonekey Rep	2013	0.85
9	Targeted treatment for sonic hedgehog-dependent medulloblastoma.	Neuro Oncol	2014	0.83
10	Bone sarcomas: from biology to targeted therapies.	Sarcoma	2012	0.82
11	MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.	FASEB J	2015	0.80
12	Medulloblastoma development: tumor biology informs treatment decisions.	CNS Oncol	2015	0.78